Gonadorelin: uses, evidence and status

compound file

The answer, first. Synthetic gonadotrophin-releasing hormone, identical to the ten-amino-acid hypothalamic hormone that drives the pituitary to release LH and FSH. The strongest evidence is for diagnostic test of pituitary gonadotrophin reserve, graded A — approval or replicated trials.

Approved in the United States as Factrel for evaluating the pituitary's capacity to release LH, application NDA018123 ¹.

Marketing status is now discontinued. The stimulation test still separates gonadotrophin deficiency from constitutional delay ⁷. The other use — keeping testicular function during testosterone therapy — grades D or E: animal or mechanism data with no controlled human outcome.

What it is used for

Every use graded on its own evidence, not the compound as a whole. 4 outcomes, ranked by what the human record supports.

#outcome · human · animal · gradewhat the best evidence actually shows

01Diagnostic test of pituitary gonadotrophin reserveFDA-approved indication · not the basisgrade AApproved in the United States as Factrel for evaluating the pituitary's capacity to release LH, application NDA018123 ¹. Marketing status is now discontinued. The stimulation test still separates gonadotrophin deficiency from constitutional delay ⁷.

02Ovulation induction in hypothalamic amenorrhoeaapproved product plus 1002 women pooled · not the basisgrade AApproved as the Lutrepulse pulsatile pump, NDA019687, now discontinued ¹. Across 35 studies and 1002 women, pulsatile GnRH gave high ovulation rates with low and mild hyperstimulation risk ².

03Spermatogenesis and virilisation in hypogonadotropic hypogonadism76-man series plus comparative trials · not the basisgrade BPulsatile GnRH normalised LH in 97% and testosterone in 93% of 76 men, sperm counts reaching a median 3 million per mL ³. A 42-case review found it as effective as hCG with hMG ⁹.

04Keeping testicular function during testosterone therapyno trial · not the basisgrade DThe men's-clinic use, and the reason most vials sell. No trial has tested it. Half-life is 5.5 to 8 minutes ⁵, and non-pulsatile exposure desensitises the pituitary rather than driving it ¹⁰.

gradewhat it means

ARegulatory approval, or multiple adequately-powered trials agreeing with each other

BAt least one well-powered human randomised trial, with the direction replicated

CSmall or open-label human trials only

DAnimal or mechanism data only, with no controlled human outcome

EA claim the human trials have already killed

How it works

The proposed mechanism, in three steps. A mechanism is a reason to run a trial, never a substitute for one.

1targetBinds the GnRH receptor on pituitary gonadotroph cells ¹⁰.

2signalPulses about once an hour sustain LH and FSH release. Continuous exposure downregulates the receptor and shuts secretion down instead ¹⁰.

3effectIn men with hypogonadotropic hypogonadism, pump-delivered pulses normalised LH in 97% and testosterone in 93% ³.

What it does not do

Claims the current record does not support. Worth knowing before you set expectations.

not supported by the evidence

A twice-weekly injection restores the axis. Nothing published supports bolus dosing on that schedule. The approved fertility product delivered a pulse every 90 minutes by pump ¹¹⁰.
Interchangeable with hCG on testosterone therapy. hCG acts at the testis, gonadorelin at the pituitary, which exogenous testosterone has already suppressed. No head-to-head trial exists.
Raises testosterone in healthy men. Never tested. Every trial enrolled patients with a diagnosed hypothalamic or pituitary defect ²³⁹.

How it is used

What published protocols administered, and what the community reports doing. Descriptive on both counts, and never a recommendation.

routeSubcutaneous or intravenous. The approved fertility use was a pump delivering pulses roughly every 90 minutes.

formatLyophilised powder, reconstituted. Pump cartridge in the discontinued fertility kit.

published dosesFactrel was supplied in 0.1, 0.2 and 0.5 mg vials for the diagnostic test ¹. Pulsatile therapy in men ran 5 to 25 nanograms per kilogram per pulse subcutaneously, titrated to a normal adult testosterone ³. Fertility protocols delivered it by pump, never as a bolus ¹².

human pharmacokineticsPlasma half-disappearance time 5.5 to 8 minutes in healthy subjects, stretching to 12 to 16.5 minutes in renal failure ⁵.

reported conventionsAs reported on men's-health forums and telehealth protocol sheets, 2022-2026: subcutaneous doses in the 100 to 200 microgram range. Two or three times weekly, or daily, alongside testosterone. No published trial uses that schedule. Convention, not guidance.

commonly paired withKisspeptin-10

This site does not publish protocols to follow. The doses above are what studies administered or what users report, stated as facts about the literature and the market. How protocols are structured, mixing and storage and the reconstitution calculator cover the arithmetic.

What to expect

Where a trial measured it, the trial. Where only the community reports it, that is said out loud.

onsetLH rises within 30 minutes of a single dose, which is what the diagnostic test reads ⁷. On pump therapy spermatogenesis took a median 6 months in one comparison ⁴. Men with no prior pubertal development had not normalised testicular volume by 24 months ³.

most common reportAs reported: nothing perceptible at the injection. Effects are read off bloodwork, not off sensation.

adverse effectsIn the pulsatile male series, skin erythema at the pump site was the common local problem ⁴. Ovarian hyperstimulation across 1002 women was low in incidence and mild in severity, with slightly raised multiple-gestation rates ².

the stop signalFertility and hypogonadism protocols run to a defined endpoint, pregnancy or a target sperm count, then stop ²³. The diagnostic use is a single dose ¹.

Approval and status

What regulators and sport bodies have actually said, separately from what the evidence shows.

approvalApproved in the US as Factrel and Lutrepulse. Both discontinued ¹.

FDATwo approved applications, NDA018123 and NDA019687, both marketing status discontinued ¹. Compounded product is what circulates.

sport [WADA]Prohibited in males at all times, class S2.2.1 ⁶.

sold asapproved medicine

Check the vial

The grade above describes a molecule studied under controlled conditions. It says nothing about the powder in a particular vial.

That gap is the one part of this market a reader can actually close. How to read a certificate of analysis covers the five measures in five minutes, and the 2026 audit grades vendors on the documents they publish against a rubric printed in full.

Questions we get

What is Gonadorelin used for?

Its approved uses are a diagnostic test of pituitary function, as Factrel, and pulsatile ovulation induction in hypothalamic amenorrhoea, as Lutrepulse ¹. Both US products are discontinued.

It also induces spermatogenesis in hypogonadotropic hypogonadism when delivered by pump ³⁹. In men's clinics it is prescribed alongside testosterone to preserve testicular function, a use with no published trial.

How is Gonadorelin used?

Descriptively. The approved fertility use is a wearable pump delivering a pulse roughly every 90 minutes, because that is what the pituitary responds to ¹¹⁰. In men, pulsatile therapy ran 5 to 25 nanograms per kilogram per pulse, titrated to testosterone ³.

The diagnostic use is one dose from a 0.1, 0.2 or 0.5 mg vial ¹. Half-life is 5.5 to 8 minutes ⁵.

How long does Gonadorelin take to work?

For the diagnostic test, LH rises within 30 minutes ⁷. For fertility, spermatogenesis on pump therapy appeared at a median 6 months in one comparison ⁴.

Men with no prior pubertal development had not normalised testicular volume by 24 months ³. For the testosterone-adjunct use, no timeline exists, because no trial has measured one.

Is Gonadorelin an approved drug?

Yes, for two specific indications, and both US products are now discontinued ¹. An approval attaches to a named indication, a named dose and a manufactured product.

It does not extend to a compounded vial, to an off-label goal, or to a twice-weekly schedule worked out on a forum. Under the World Anti-Doping Code it is prohibited in males at all times, class S2.2.1 ⁶.

References

US Food and Drug Administration. Drugs@FDA. FACTREL, NDA018123, gonadorelin hydrochloride, and LUTREPULSE KIT, NDA019687, gonadorelin acetate. Accessed 24 August 2026. accessdata.fda.gov
Tranoulis A, et al. Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and functional hypothalamic amenorrhea: a systematic review of the literature and a meta-analysis. Fertil Steril. 2018. PMID 29605411
Pitteloud N, et al. Predictors of outcome of long-term GnRH therapy in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2002. PMID 12213860
Zhang L, et al. The Pulsatile Gonadorelin Pump Induces Earlier Spermatogenesis Than Cyclical Gonadotropin Therapy in Congenital Hypogonadotropic Hypogonadism Men. Am J Mens Health. 2019. PMID 30569789
Pimstone B, et al. Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure. J Clin Endocrinol Metab. 1977. PMID 320223
World Anti-Doping Agency. The 2026 Prohibited List. In force 1 January 2026. wada-ama.org
Sun QH, et al. Role of Gonadotropin-releasing Hormone Stimulation Test in Diagnosing Gonadotropin Deficiency in Both Males and Females with Delayed Puberty. Chin Med J [Engl]. 2015. PMID 26365959
Quaas P, et al. Use of pulsatile gonadotropin-releasing hormone [GnRH] in patients with functional hypothalamic amenorrhea [FHA] results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. J Assist Reprod Genet. 2022. PMID 36378460
Buchter D, et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol. 1998. PMID 9758439
Belchetz PE, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 1978. PMID 100883

Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here, and this page carries no vendor link. Grades follow the published criteria in our editorial policy — never referral terms. Research and education only. Not medical advice.